A Phase 1, Single-center, Partially Double-blind, Randomized, Single-dose, 3-Period Crossover Study to Assess the Pharmacodynamic Effects of LX4211 and INVOKANA (Canagliflozin) in Healthy Subjects Using Stable Isotope Tracer Methods
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2019
Price : $35 *
At a glance
- Drugs Sotagliflozin (Primary) ; Canagliflozin
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Lexicon Pharmaceuticals
- 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.